BPC-157
5 mg
$29.00
BPC-157 5 mg + TB-500 5 mg combo blend, supplied as a lyophilized (freeze-dried) peptide powder vial paired with a separate vial of bacteriostatic water for reconstitution. Mix on-site just before first use.
For research and clinical use only. Supplied to licensed practitioners and research professionals. Not evaluated by the FDA.
BPC-157 5 mg + TB-500 5 mg combo blend, supplied as a lyophilized (freeze-dried) peptide powder vial paired with a separate vial of bacteriostatic water for reconstitution. Mix on-site just before first use.
Supplied to licensed practitioners and research professionals only. The TB-500 component is shear-sensitive — reconstitute gently and do not vortex. Store lyophilized at −20 °C; use reconstituted material within 14 days held at 2–8 °C. Not evaluated by the FDA and not intended to diagnose, treat, cure or prevent any disease.
| Available sizes | 5 mg + 5 mg — $69.00 |
| Form | Lyophilized powder + BAC water vial |
| Molecular weight | 1419.5 / 4963.4 g/mol |
| CAS | 137525-51-0 / 885340-08-9 |
| Sequence length | 15 / 20 |
| Storage — sealed | −20 °C, protected from light |
| Storage — reconstituted | 2–8 °C, use within 14 days |
| Ships from | Chicago, IL |
| SKU | PEP-BPCTB-55 |
Research summary — for laboratory and research use only. Not medical advice, not a dosing recommendation, and not an FDA evaluation of safety or efficacy.
This is a formulated blend of two independently characterized research peptides: BPC-157 (see its own product page for origin) and TB-500, a synthetic version of the actin-binding region of Thymosin β4, a naturally occurring protein studied since the 1990s for its role in cell migration and wound repair.
TB-500 binds monomeric actin (G-actin), which in preclinical models has been linked to increased cell migration, reduced inflammatory signalling, and support of new blood-vessel formation. Combining it with BPC-157 is a common research design intended to probe complementary angiogenic and tissue-repair pathways in the same injury model, rather than a single validated mechanism of its own.
TB-500's actin-binding property is the basis for research into cell motility and migration in wound-healing and cardiac-repair models.
Research groups sometimes pair BPC-157 and TB-500 in the same soft-tissue injury model to compare additive versus independent effects.
Both components have separately been studied for down-stream effects on inflammatory markers in rodent injury models.
Supplied to licensed practitioners and research professionals only. The TB-500 component is shear-sensitive — reconstitute gently and do not vortex. Store lyophilized at −20 °C; use reconstituted material within 14 days held at 2–8 °C. Not evaluated by the FDA and not intended to diagnose, treat, cure or prevent any disease.
It's a common research pairing — investigators studying tissue-repair pathways often compare or combine the two in the same model. The blend vial is a convenience format, not a claim that the combination has a distinct approved mechanism.
Further reading: for the published preclinical and clinical literature on BPC-157 + TB-500, search PubMed. We link to the search rather than cherry-picked citations so you can review the current, full body of literature yourself.